MSN: One symptom that predicts how bad your coronavirus case will be
UC researcher says the nose offers a clue by the third day of infection
Ahmad Sedaghat, MD, PhD, found in a study of 103 Swiss patients diagnosed with COVID-19, patients were most likely to show loss of a sense of smell by the third day of infection with the novel virus. Most patients also experienced a loss of the sense of taste.
Sedaghat, an associate professor in the UC College of Medicine’s Department of Otolaryngology-Head and Neck Surgery and an UC Health physician specializing in diseases of the nose and sinuses, said at least 61 percent of patients reported reduced or loss sense of smell. The mean onset for reduction or loss in the sense of smell was 3.4 days.
The findings were picked up by various national and international media outlets including The Economic Times, MSN, The Times of India, and Spectrum News (starts at 9:17).
Read more about the research online.
Related Stories
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.